Activated CD8+ T-lymphocytes in obstructive sleep apnoea

European Respiratory Journal

Volumn 25, Issue 5, 2005, Pages 820-828

  Dyugovskaya, L ^a   Lavie, P ^a   Hirsh, M ^a   Lavie, Lenal ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Atherosclerosis; CD8+ T lymphocytes; Cytotoxicity; Nasal continuous positive airway pressure treatment; Obstructive sleep apnoea; Perforin

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CHROMIUM 51; PERFORIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; ATHEROSCLEROSIS; BIOASSAY; CELL STRAIN K 562; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPOTHESIS; MALE; PHENOTYPE; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SLEEP APNEA SYNDROME; T LYMPHOCYTE ACTIVATION; TARGET CELL; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANTIGENS, CD56; BIOLOGICAL MARKERS; CD8-POSITIVE T-LYMPHOCYTES; CONTINUOUS POSITIVE AIRWAY PRESSURE; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PORE FORMING CYTOTOXIC PROTEINS; RECEPTORS, IGG; RECEPTORS, IMMUNOLOGIC; SLEEP APNEA, OBSTRUCTIVE; UMBILICAL VEINS;

EID: 18744374666     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00103204     Document Type: Article

References (33)

1. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnea syndrome as a risk factor for hypertension: population study. BMJ 2000; 320: 479-482.
2. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19-25.
3. Nachtmann A, Stang A, Wang Y-M, Wondzinski E, Thilmann A. Association of obstructive sleep apnea and stenotic artery disease in ischemic stroke patients. Atherosclerosis 2003; 169: 301-307.
4. Malhotra A, White DP. Obstructive sleep apnoea. Lancet 2002; 360: 237-245.
5. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890.
6. Ludewig B, Zinkernagel RM, Hengartner H. Arterial inflammation and atherosclerosis. Trends Cardiovasc Med 2002; 12: 154-159.
7. Song L, Leung C, Schindler C. Lymphocytes are important in early atherosclerosis. J Clin Invest 2001; 108: 251-259.
8. Zhou X, Hansson GK. Immunomodulation and vaccination for atherosclerosis. Expert Opin Biol Ther 2004; 4: 599-612.
9. Sherer Y, Shoenfeld Y. Immunomodulation for treatment and prevention of atherosclerosis. Autoimmun Rev 2002; 1: 21-27.
10. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004; 27: 123-128.
11. Lavie L. Obstructive sleep apnoea syndrome: an oxidative stress disorder. Sleep Med Rev 2003; 7: 35-51.
12. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002; 165: 934-939.
13. Dyugovskaya L, Lavie P, Lavie L. Phenotypic and functional characterization of blood gammadelta T cells in sleep apnea. Am J Respir Crit Care Med 2003; 168: 242-249.
14. Mingari MC, Ponte M, Vitale C, Bellomo R, Moretta L. Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum Immunol 2000; 61: 44-50.
15. Moretta L, Romagnani C, Pietra G, Moretta A, Mingari MC. NK-CTLs, a novel HLA-E-restricted T-cell subset. Trends Immunol 2003; 24: 136-143.
16. Satoh M, Seki S, Hashimoto W, et al. Cytotoxic gamma/delta or alpha/beta T-cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol 1996; 157: 3886-3892.
17. Werwitzke S, Tiede A, Drescher BE, Schmidt RE, Witte T. CD8beta/CD28 expression defines functionally distinct populations of peripheral blood T lymphocytes. Clin Exp Immunol 2003; 133: 334-343.
18. Pittet NJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T-cells closely correlates with CD56 surface expression. J Immunol 2000; 164: 1148-1152.
19. Zamai L, Mariani AR, Zauli G, et al. Kinetics of in vitro natural killer activity against K562 cells as detected by flow cytometry. Cytometry 1998; 32: 280-285.
20. Jacobs R, Hintzen G, Kemper A, et al. CD56bright cells differ in their KIR receptoire and cytotoxic features from CD56bright NK cells. Eur J Immunol 2001; 31: 3221-3227.
21. Lima M, Teixeira MA, Queiros ML, et al. Immunophenotypic characterization of normal blood CD56+lo versus CD56hi NK-cell subsets and its impact on the understanding of their tissue distribution and functional properties. Blood Cells Mol Dis 2001; 27: 731-743.
22. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56 (bright) subset. Blood 2001; 97: 3146-3151.
23. Tayebi H, Kuttler F, Saas P, et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp Hematol 2001; 29: 458-470.
24. Campbell JJ, Qin S, Unutmaz D, et al. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 2001; 166: 6477-6482.
25. Frey M, Packianathan NB, Fehniger TA, et al. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer subsets. J Immunol 1998; 161: 400-408.
26. Solana R, Mariani E. NK and NK/T cells in human senescence. Vaccine 2000; 18: 1613-1620.
27. Nakajima H, Moore YI, Takiguchi M. Functional expression of the NKB1 killer cell inhibitory receptors on a gamma/delta CTL clones. Immunogenetics 1997; 45: 226-228.
28. Caldwell CC, Kojima H, Lukashev D, et al. Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol 2001; 167: 6140-6149.
29. Peled N, Greenberg A, Pillar G, Zinder O, Levi N, Lavie P. Contributions of hypoxia and respiratory disturbance index to sympathetic activation and blood pressure in obstructive sleep apnea syndrome. Am J Hypertens 1998; 11: 1284-1289.
30. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve: an integrative interference between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52: 595-638.
31. Hellstrand K, Hermodsson S. An immunopharmacological analysis of adrenaline-induced suppression of human natural killer cytotoxicity. Int Arch Allergy Appl Immunol 1989; 89: 334-341.
32. Irwin M. Effects of sleep loss on immunity. Brain Behav Immun 2002; 16: 503-512.
33. Irwin M, Clark C, Kennedy B, Gillin GC, Ziegler M. Nocturnal catecholamines and immune function in insomniacs, depressed patients and control subjects. Brain Behav Immun 2003; 17: 365-372.